Re: Zenith-Oncology Pipeline
in response to
by
posted on
Mar 23, 2021 09:16AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
As there currently isn't any real market for Zenith other than the OTC I would say that the value is what someone would pay for a LARGE # of shares, not the paltry few thousand that trade daily.
Market Cap is just math. Shares outstanding x price. It's not a guesstimate of what people hope/think the company might be worth. Some folks think the ZHCLF price is artifically low, but if just a handful of buyers thought it was a bargain, the price would zoom up because of the low liquidity. IMO the price reflects the untrue rumours that come and go, and the lack of confidence that we will see "unlocked shareholder value" in our pockets anytime in the foreseeable future.